Literature DB >> 12644016

Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression.

Evangelia Skarpidi1, Hua Cao, Birgit Heltweg, Brian F White, Ronald L Marhenke, Manfred Jung, George Stamatoyannopoulos.   

Abstract

OBJECTIVE: To examine whether hydroxamic acids are inducers of fetal hemoglobin expression, we tested the effects on gamma gene expression of butyric and propionic hydroxamic acids and of two other hydroxamic acids (SBHA and SAHA), which are potent inhibitors of histone deacetylase (HDAC). We also investigated whether there is a correlation between HDAC inhibitory activity of the compounds and their ability to induce gamma-globin gene expression.
MATERIALS AND METHODS: Effects on gamma-globin expression were assessed by two methods: 1) a screening assay in which specific gamma-globin gene inducers are recognized by their ability to increase gamma firefly luciferase activity significantly more than beta-renilla luciferase activity; and 2) measurements of gamma-globin mRNA and the frequency of fetal hemoglobin-positive erythroblasts in cultures of burst-forming unit erythroid (BFU-E) from normal individuals. HDAC in vitro activity was measured with a partially purified rat liver HDAC and a fluorogenic substrate.
RESULTS: All compounds tested increased gamma firefly luciferase activity, gamma/gamma+beta mRNA ratios, and percentage of fetal hemoglobin-containing erythroblasts in BFU-E cultures, in a dose-dependent fashion. Butyryl-hydroxamic acid 100 microM increased the gamma/gamma+beta mRNA ratios by 5.8-fold and the frequency of fetal hemoglobin-containing erythroblasts by 4.1-fold. Propionyl-hydroxamic acid 150 microM increased the gamma/gamma+beta ratios by 6.3-fold and the fetal hemoglobin-containing erythroblasts by 3.9-fold. SBHA induced gamma-globin gene expression at very low concentrations, 5 to 20 microM in the luciferase system and 2 to 8 microM in BFU-E cultures; SAHA at 1 to 7.5 microM in the luciferase system and 1 to 2.5 microM in the BFU-E cultures. HDAC in vitro inhibition was observed in the millimolar range for propionate and butyrate. IC(50) determinations led to values of 384 microM for propionyl-hydroxamate, 47 microM for butyryl-hydroxamate, 0.93 microM for SBHA, and 0.26 microM for SAHA. CONCLUCION: Our data indicate that hydroxamic acid-based HDAC inhibitors are potent gamma-globin gene inducers and that the concentration range of their effects on gamma gene expression can be correlated roughly with their HDAC inhibitory potencies. Copyright 2003 International Society for Experimental Hematology

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644016     DOI: 10.1016/s0301-472x(02)01030-5

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Induction of human gamma globin gene expression by histone deacetylase inhibitors.

Authors:  Hua Cao; George Stamatoyannopoulos; Manfred Jung
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

2.  Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Authors:  Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz
Journal:  Br J Haematol       Date:  2009-10-28       Impact factor: 6.998

3.  Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models.

Authors:  Regine Bohacek; Michael S Boosalis; Colin McMartin; Douglas V Faller; Susan P Perrine
Journal:  Chem Biol Drug Des       Date:  2006-05       Impact factor: 2.817

4.  Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.

Authors:  Susan P Perrine; Serguei A Castaneda; Michael S Boosalis; Gary L White; Brandon M Jones; Regine Bohacek
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

5.  Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.

Authors:  Daniel M Fass; Rishita Shah; Balaram Ghosh; Krista Hennig; Stephanie Norton; Wen-Ning Zhao; Surya A Reis; Peter S Klein; Ralph Mazitschek; Rebecca L Maglathlin; Timothy A Lewis; Stephen J Haggarty
Journal:  ACS Med Chem Lett       Date:  2010-10-08       Impact factor: 4.345

6.  Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.

Authors:  Robert A Parise; Jan H Beumer; Cyrous O Kangani; Julianne L Holleran; Julie L Eiseman; Nicola F Smith; Joseph M Covey; Susan P Perrine; Merrill J Egorin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-08       Impact factor: 3.205

7.  A new amidohydrolase from Bordetella or Alcaligenes strain FB188 with similarities to histone deacetylases.

Authors:  Christian Hildmann; Milena Ninkovic; Rüdiger Dietrich; Dennis Wegener; Daniel Riester; Thomas Zimmermann; Olwen M Birch; Christine Bernegger; Peter Loidl; Andreas Schwienhorst
Journal:  J Bacteriol       Date:  2004-04       Impact factor: 3.490

8.  Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives.

Authors:  Susan P Perrine; Rishikesh Mankidy; Michael S Boosalis; James J Bieker; Douglas V Faller
Journal:  Eur J Haematol       Date:  2009-02-05       Impact factor: 2.997

Review 9.  Update on fetal hemoglobin gene regulation in hemoglobinopathies.

Authors:  Daniel E Bauer; Stuart H Orkin
Journal:  Curr Opin Pediatr       Date:  2011-02       Impact factor: 2.856

10.  Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2.

Authors:  Jeffrey R Shearstone; Olga Golonzhka; Apurva Chonkar; David Tamang; John H van Duzer; Simon S Jones; Matthew B Jarpe
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.